BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TH9619 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of TH9619\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07151040-2766@assetmemo.bio
DTSTAMP:20261121T005347Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:TH9619: Phase 1/2 readout est. (NCT07151040)
DESCRIPTION:TH9619\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Phase 
 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors\nEs
 timated primary completion: December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/th9619#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07151040
URL:https://assetmemo.bio/drug/th9619#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
